Skip to main content
TipRanks
Go Ultimate75% OFF

IMPACT Therapeutics, Inc. Class H (7630) Ratios

IMPACT Therapeutics, Inc. Class H Ratios

HK:7630's free cash flow for Q2 2026 was $3.53M. For the 2026 fiscal year, HK:7630's free cash flow was decreased by $-22.57K and operating cash flow was $3.55M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23
Liquidity Ratios
Current Ratio3.084.180.81
Quick Ratio2.824.130.81
Cash Ratio2.472.570.74
Solvency Ratio-0.22-0.220.03
Operating Cash Flow Ratio-0.89-0.980.06
Short-Term Operating Cash Flow Coverage-25.54-48.930.00
Net Current Asset Value$ -138.71M$ -103.91M$ -14.54M
Leverage Ratios
Debt-to-Assets Ratio2.582.220.00
Debt-to-Equity Ratio-0.90-1.160.00
Debt-to-Capital Ratio-8.987.260.00
Long-Term Debt-to-Capital Ratio-8.447.640.00
Financial Leverage Ratio-0.35-0.52-3.25
Debt Service Coverage Ratio-3.11-3.36-35.46
Interest Coverage Ratio-3.35-3.74-49.53
Debt to Market Cap0.080.110.00
Interest Debt Per Share0.480.630.00
Net Debt to EBITDA-2.75-3.2313.60
Profitability Margins
Gross Profit Margin84.20%75.53%96.58%
EBIT Margin-601.22%-593.78%-12.02%
EBITDA Margin-589.52%-573.94%-8.61%
Operating Profit Margin-601.22%-619.28%-12.02%
Pretax Profit Margin-773.63%-759.39%-8.48%
Net Profit Margin-773.64%-759.40%1.56%
Continuous Operations Profit Margin-773.64%-759.40%-8.48%
Net Income Per EBT100.00%100.00%-18.43%
EBT Per EBIT128.68%122.62%70.50%
Return on Assets (ROA)-86.14%-66.74%1.19%
Return on Equity (ROE)30.08%34.87%-3.87%
Return on Capital Employed (ROCE)-97.47%-70.70%44.34%
Return on Invested Capital (ROIC)-95.95%-70.28%44.34%
Return on Tangible Assets-87.36%-67.35%1.21%
Earnings Yield-2.78%-3.29%0.07%
Efficiency Ratios
Receivables Turnover5.000.000.00
Payables Turnover0.120.120.14
Inventory Turnover0.221.920.00
Fixed Asset Turnover6.253.72145.72
Asset Turnover0.110.090.76
Working Capital Turnover Ratio0.150.320.00
Cash Conversion Cycle-1346.25-2769.87-2671.70
Days of Sales Outstanding72.940.000.00
Days of Inventory Outstanding1672.94189.890.00
Days of Payables Outstanding3092.132959.762671.70
Operating Cycle1745.88189.890.00
Cash Flow Ratios
Operating Cash Flow Per Share-0.05-0.060.02
Free Cash Flow Per Share-0.05-0.060.02
Dividend Paid and CapEx Coverage Ratio-63.50-50.9463.79
Capital Expenditure Coverage Ratio-63.50-50.9463.79
Operating Cash Flow Coverage Ratio-0.11-0.100.00
Operating Cash Flow to Sales Ratio-2.51-2.570.09
Free Cash Flow Yield-0.91%-1.14%0.39%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-35.85-30.391519.99
Price-to-Sales (P/S) Ratio278.67230.7723.74
Price-to-Book (P/B) Ratio-10.84-10.60-58.76
Price-to-Free Cash Flow (P/FCF) Ratio-109.45-87.93258.55
Price-to-Operating Cash Flow Ratio-111.17-89.65254.50
Price-to-Earnings Growth (PEG) Ratio2.150.010.00
Enterprise Value Multiple-50.02-43.43-262.23
Enterprise Value1.57B1.17B751.03M
EV to EBITDA-50.02-43.43-262.23
EV to Sales294.87249.2922.57
EV to Free Cash Flow-115.81-94.98245.80
EV to Operating Cash Flow-117.64-96.85241.95
Tangible Book Value Per Share-0.50-0.51-0.10
Shareholders’ Equity Per Share-0.50-0.51-0.09
Tax and Other Ratios
Effective Tax Rate-0.00-0.000.00
Revenue Per Share0.020.020.23
Net Income Per Share-0.15-0.180.00
Tax Burden1.001.00-0.18
Interest Burden1.291.280.71
Research & Development to Revenue4.705.780.91
SG&A to Revenue2.151.160.17
Stock-Based Compensation to Revenue0.000.000.00
Income Quality0.320.345.97

Currency in USD